What is SpacePharma?
SpacePharma operates as a pioneering Swiss-Israeli biotechnology enterprise dedicated to the execution of complex scientific experiments within microgravity environments. Founded by Yossi Yamin, a veteran of the Israeli Defense Forces satellite division, the company distinguishes itself as the first private entity specifically architected to bridge the gap between aerospace engineering and pharmaceutical R&D. By leveraging the unique physical properties of space, SpacePharma aims to unlock novel molecular structures and manufacturing processes that are unattainable under terrestrial gravity. The company maintains a robust global footprint, with specialized facilities including a Space Life Sciences Lab in Florida, positioning it as a critical infrastructure provider for the next generation of space-based medical innovation.
How much funding has SpacePharma raised?
SpacePharma has raised a total of $2.1M across 1 funding round:
Grant
$2.1M
Grant (2024): $2.1M with participation from European Union
Key Investors in SpacePharma
European Union
A supranational political and economic union that provides strategic grants and funding to foster innovation, economic interdependence, and scientific advancement across its member states.
What's next for SpacePharma?
The recent capital allocation is expected to catalyze the expansion of SpacePharma's proprietary orbital laboratory infrastructure and enhance its R&D throughput. As the company moves into this next phase of growth, the focus will likely shift toward optimizing the scalability of its microgravity manufacturing processes and deepening partnerships with global pharmaceutical conglomerates. By refining its operational efficiency in Exploration Park and beyond, SpacePharma is well-positioned to capitalize on the increasing demand for high-precision biological research, effectively transforming the orbital environment into a viable, high-value industrial asset for the global healthcare market.
See full SpacePharma company page
